Instructions for Phosphogliv (Phospholipid, Glycyrrhizic acid) lyophilisate for solution preparation
English product name
Phosphogliv
Dosage form
lyophilisate for cooking. solution d/v/v administration: fl. 2.5g five pieces included. with solvent
Description:
Lyophilisate for the preparation of a solution for intravenous administration in the form of a mass from white to light yellow color.
1 fl.
phospholipids (lipoid C100) 500 mg
sodium glycyrrhizinate (trisodium salt of glycyrrhizic acid) 200 mg
2.5 g - glass bottles (5) complete with solvent water d /i (amp. 10 ml 5 pcs.) - contour plastic packaging (1) - cardboard packs.
ATX Codes
Preparations for the treatment of liver diseases A05BA
Clinical and pharmacological groups / Group affiliation
Hepatoprotector with immunomodulatory and antiviral action
Active ingredient
sodium glycyrrhizinate
phospholipids
Pharmaco-therapeutic group Phosphogliv
Hepatoprotective agent
Storage conditions
The drug should be stored out of the reach of children, protected from light at a temperature not exceeding 20 ° C. The period is two years.
Testimony Phosphogliv:
- viral hepatitis (acute and chronic);
- fatty degeneration of the liver (hepatosis);
- other liver damage (medicinal, alcoholic, toxic);
- cirrhosis of the liver;
- intoxication;
- psoriasis;
- neurodermatitis;
- eczema.
Dosage, Course and Dosage Phosphogliv:
Adults and children over twelve years of age: intravenously, having previously dissolved the powder in 10 ml of water for injection. Intravenous administration should be carried out slowly. Inject 10 ml daily 2 times / day in the morning and evening for 10 days, followed by a transition to oral administration of the drug in the form of capsules. The duration of the course can be increased on the recommendation of a doctor.
Use in children
Contraindication: children under 12 years of age.
- Nosology (ICD codes)
- B15
- Acute hepatitis A
- B16
- Acute hepatitis B
- B17.1
- Acute hepatitis C
- B18.1
- Chronic viral hepatitis B without delta agent
- B18.2
- Chronic viral hepatitis C
- K70
- Alcoholic liver disease
- K71
- Toxic liver damage
- K73
- Chronic hepatitis not classified under other headings
- K74
- Fibrosis and cirrhosis of the liver
- L20.8
- Other atopic dermatitis (neurodermatitis, eczema)
- L40
- Psoriasis
pharmachologic effect:
Combined drug Phosphogliv.
It has a membrane-stabilizing, hepatoprotective and antiviral effect.
Phosphatidylcholine (the main component of phospholipids) is the main structural element of cellular and intracellular membranes, is able to restore their structure and functions when damaged, providing a cytoprotective effect. Normalizes protein and lipid metabolism, prevents the loss of enzymes and other active substances by hepatocytes, restores the detoxifying function of the liver, inhibits the formation of connective tissue, reducing the risk of liver fibrosis and cirrhosis.
